Search results
Results from the WOW.Com Content Network
Therefore, almost all new epilepsy drugs are initially approved only as adjunctive (add-on) therapies. Patients whose epilepsy is uncontrolled by their medication (i.e., it is refractory to treatment) are selected to see if supplementing the medication with the new drug leads to an improvement in seizure control.
Levetiracetam, sold under the brand name Keppra among others, is a novel antiepileptic drug [7] used to treat epilepsy. [8] It is used for partial-onset, myoclonic, or tonic–clonic seizures, [7] and is taken either by mouth as an immediate or extended release formulation or by injection into a vein.
Carbamazepine, sold under the brand name Tegretol among others, is an anticonvulsant medication used in the treatment of epilepsy and neuropathic pain. [4] [1] It is used as an adjunctive treatment in schizophrenia along with other medications and as a second-line agent in bipolar disorder.
A severe head injury, such as one sustained in a motor vehicle accident, fall, assault, or sports injury, can result in one or more seizures that can occur immediately after the fact or up to a significant amount of time later. [34] This could be hours, days, or even years following the injury.
For premium support please call: 800-290-4726 more ways to reach us
In the United States, cenobamate is indicated for the treatment of partial-onset seizures in adults. [3]In the European Union, it is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalization in adults with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medications.
*The meaning of these findings for day-to-day care is not clear In a 2013 comparison of 15 antipsychotics in effectiveness in treating schizophrenia, quetiapine demonstrated standard effectiveness. It was 13–16% more effective than ziprasidone , chlorpromazine , and asenapine and approximately as effective as haloperidol and aripiprazole .
Eslicarbazepine acetate (ESL), sold under the brand names Aptiom and Zebinix among others, is an anticonvulsant medication approved for use in Europe and the United States as monotherapy or as additional therapy for partial-onset seizures epilepsy. [6] [4] [3] Similarly to oxcarbazepine, ESL behaves as a prodrug to (S)-(+)-licarbazepine. [7]